NADAC acquisition cost data for PLAVIX 75 MG TABLET. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 63653117101 | $7.17 | 2022-01-03 | Rx |
| 63653117101 | $7.17 | 2022-01-03 | Rx |
| 63653117101 | $7.17 | 2022-01-03 | Rx |
| 63653117101 | $7.17 | 2022-01-03 | Rx |
| 63653117101 | $7.17 | 2022-01-03 | Rx |
| 63653117101 | $7.17 | 2022-01-03 | Rx |
| 63653117101 | $7.17 | 2022-01-03 | Rx |
| 63653117101 | $7.17 | 2022-01-03 | Rx |
| 63653117101 | $7.17 | 2022-01-03 | Rx |
| 63653117101 | $7.17 | 2022-01-03 | Rx |
Generic: Clopidogrel Bisulfate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | 6,794 | N/A |
| 2020 | $2.7M | 5,928 | 5,648 | $6.60 |
| 2021 | $8.0M | 17,783 | 4,533 | $7.06 |
| 2022 | $7.7M | 16,019 | 3,868 | $7.53 |
| 2023 | $7.2M | 14,057 | 3,289 | $8.02 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $1.2M | 2,479 | 508 |
| California | $970.2K | 1,905 | 434 |
| Florida | $594.5K | 1,067 | 278 |
| New Jersey | $495.7K | 1,003 | 239 |
| Pennsylvania | $426.6K | 858 | 194 |
| Texas | $313.9K | 548 | 144 |
| South Carolina | $285.0K | 445 | 151 |
| Ohio | $246.4K | 470 | 114 |
| Puerto Rico | $217.0K | 676 | 107 |
| North Carolina | $199.7K | 380 | 90 |
| Illinois | $192.9K | 383 | 108 |
| Georgia | $175.0K | 334 | 78 |
| Michigan | $152.2K | 275 | 75 |
| Connecticut | $124.6K | 210 | 56 |
| Tennessee | $115.8K | 199 | 56 |
| Kentucky | $114.2K | 217 | 50 |
| Massachusetts | $108.7K | 202 | 49 |
| Virginia | $107.7K | 193 | 51 |
| Wisconsin | $106.7K | 215 | 45 |
| Indiana | $95.0K | 186 | 54 |
| Maryland | $90.4K | 145 | 47 |
| Arizona | $80.6K | 137 | 37 |
| Alabama | $79.9K | 172 | 39 |
| Louisiana | $68.4K | 128 | 32 |
| Washington | $61.4K | 111 | 28 |
| Minnesota | $48.5K | 91 | 24 |
| Missouri | $48.1K | 107 | 23 |
| Hawaii | $47.8K | 78 | 20 |
| Nevada | $46.8K | 84 | 24 |
| West Virginia | $45.9K | 102 | 23 |
| Arkansas | $32.8K | 57 | 15 |
| Colorado | $32.8K | 70 | 18 |
| Mississippi | $32.8K | 66 | 19 |
| Delaware | $31.2K | 48 | 14 |
| Oklahoma | $29.0K | 42 | 15 |
| Iowa | $25.1K | 45 | 12 |
| Kansas | $24.6K | 51 | 12 |
| New Hampshire | $24.0K | 37 | 11 |
| Maine | $23.0K | 39 | N/A |
| Alaska | $21.1K | 38 | 11 |
| Oregon | $20.6K | 35 | 13 |
| Rhode Island | $17.9K | 30 | N/A |
| New Mexico | $12.9K | 20 | N/A |
| Utah | $9.6K | 14 | N/A |
| Vermont | $7.7K | 14 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.